flowchart TD
A["Ferroptosis"] --> |"regulates"| B["Iron Metabolism"]
A --> |"regulates"| C["Lipid Peroxidation"]
A --> |"regulates"| D["Cysteine Metabolism"]
B --> |"promotes"| E["ROS Generation"]
C --> |"produces"| F["Lipid Peroxides"]
D --> |"depletes"| G["Glutathione"]
E --> |"oxidizes"| H["Membrane Lipids"]
F --> |"damages"| I["Cell Membrane"]
G --> |"impairs"| J["Antioxidant Defense"]
H --> |"leads to"| I
J --> |"enhances"| C
I --> |"causes"| K["Neuronal Death"]
A --> |"causes"| L["Alzheimers Disease"]
A --> |"associated_with"| M["Parkinsons Disease"]
A --> |"associated_with"| N["ALS"]
K --> |"contributes to"| O["Neurodegeneration"]
classDef central fill:#006494,color:#e0e0e0
classDef pathological fill:#ef5350,color:#0d0d1a
classDef regulatory fill:#4a1a6b,color:#e0e0e0
classDef protective fill:#1b5e20,color:#e0e0e0
classDef outcomes fill:#5d4400,color:#e0e0e0
class A central
class B,C,D regulatory
class E,F,H,I,K pathological
class G,J protective
class L,M,N,O outcomes
This experiment validates the [Ferroptosis Hypothesis](/mechanisms/ferroptosis) by measuring [ferroptosis](/mechanisms/ferroptosis) markers in [Parkinson's disease](/diseases/parkinsons-disease) patient samples, testing [ferroptosis](/mechanisms/ferroptosis) inhibition in cellular models, and evaluating [iron chelation therapy](/therapeutics/iron-chelation-therapy-neurodegeneration) in early-stage [PD](/diseases/parkinsons-disease). [Ferroptosis](/mechanisms/ferroptosis) is an iron-dependent, [lipid peroxidation](/mechanisms/oxidative-stress)-driven form of cell death that has been implicated in [dopaminergic neuron](/cell-types/dopaminergic-neurons-substantia-nigra) loss in the [substantia nigra](/brain-regions/substantia-nigra) of [PD](/diseases/parkinsons-disease) patients[@ayton2022;@devos2020]. The [GPX4](/proteins/gpx4) antioxidant system is compromised in [PD](/diseases/parkinsons-disease), making [neurons](/cell-types/dopaminergic-neurons-substantia-nigra) vulnerable to [ferroptosis](/mechanisms/ferroptosis)-mediated death[@weiland2019].
Study Design
Phase 1: Biomarker Discovery (Months 1-12)
Objectives
Identify ferroptosis biomarkers in PD patients vs. controls
Biomarker validation: 3-5 ferroptosis biomarkers for PD diagnosis/progression
Mechanistic validation: Direct evidence of ferroptosis in PD neurons
Therapeutic proof-of-concept: Safety of iron chelation in PD
Trial design: Foundation for Phase III efficacy trial
Related Mechanisms and Therapeutic Targets
This experiment connects [ferroptosis](/mechanisms/ferroptosis) to broader [neurodegenerative pathways](/mechanisms) relevant to [Parkinson's disease](/diseases/parkinsons-disease):
Key Mechanisms
[Iron dysregulation](/mechanisms/metal-homeostasis-alzheimers): [Parkinson's disease](/diseases/parkinsons-disease) patients show elevated iron in the [substantia nigra](/brain-regions/substantia-nigra), creating a pro-ferroptotic environment
[Oxidative stress](/mechanisms/oxidative-stress): [Lipid peroxidation](/mechanisms/oxidative-stress) is elevated in [PD](/diseases/parkinsons-disease); [4-HNE](/mechanisms/oxidative-stress) and [F2-isoprostanes](/mechanisms/oxidative-stress) are markers of this process
[Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction): [Dopaminergic neurons](/cell-types/dopaminergic-neurons-substantia-nigra) are particularly sensitive to [mitochondrial](/mechanisms/mitochondrial-dysfunction) dysfunction, which synergizes with [ferroptosis](/mechanisms/ferroptosis)
[Neuroinflammation](/mechanisms/neuroinflammation): Microglial [iron](/mechanisms/metal-homeostasis-alzheimers) accumulation drives [neuroinflammation](/mechanisms/neuroinflammation), creating a feedforward loop with [ferroptosis](/mechanisms/ferroptosis)
[Protein aggregation](/mechanisms/alpha-synuclein-pathology): [Alpha-synuclein](/proteins/alpha-synuclein) aggregates can disrupt [GPX4](/proteins/gpx4) function, linking [synucleinopathy](/diseases/parkinsons-disease) to [ferroptosis](/mechanisms/ferroptosis)
System Xc- inhibitors: Block cystine uptake, creating pro-ferroptotic conditions (therapeutic target to avoid)
References
[Ayton et al., Ferroptosis contributes to dopaminergic neuron loss in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)
[Devos et al., Targeting ferroptosis for neuroprotection in PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)
[Friedman et al., Deferoxamine for early Parkinson disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)
Pathway Diagram
The following diagram shows the key molecular relationships involving Ferroptosis Validation in Parkinson's Disease discovered through SciDEX knowledge graph analysis: